logo/base Created with Sketch.

Highlights from 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan® Mitigates Risk of Patients Developing Fibrosis/Cirrhosis

Echosens is pleased to report that the FibroScan® family of products was well received at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, with our solutions referenced in 19 oral presentations and 179 poster presentations.

Attendees learned about new results demonstrating the clinical usefulness of liver and spleen stiffness measurement by VCTE™, as well as CAP™ and the performances of Fast™, Agile 3+, Agile 4 and FibroMeter VCTE™ scores in many different settings. 

Non-invasive FibroScan® is an innovative technology that advances efforts to halt the progression of fatty liver disease (FLD) and empowers healthcare providers with an accurate, point-of-care tool to measure liver fat and stiffness. FLD includes nonalcoholic fatty liver disease (NAFLD), the accumulation of liver fat in people who drink little or no alcohol, and its more severe form nonalcoholic steatohepatitis (NASH).

Better assessment tools in primary care reduces unnecessary specialist referrals, as well as invasive and expensive diagnostic testing.


Three FibroScan® Technology Tools

FibroScan® is acknowledged worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines across 100+ countries.  

1/ FibroScan® Expert 630 is a complete non-invasive solution that provides effective risk stratification of patients with advanced chronic liver disease and portal hypertension (PH). This advanced tool takes liver disease management to the next level by offering 1) enhanced ergonomics, advanced features and high-speed processing for optimized exam efficiency and 2) expanded clinical capabilities with a dedicated spleen stiffness measurement (SSM) mode and embedded ultrasound guidance system to simplify both liver and spleen targeting

2/ FibroScan® Fast is a tool—available on the myFibroScan app—to help clinicians cost-effectively identify individuals at risk for active fibrotic NASH, an asymptomatic, progressive and burgeoning liver disease that can lead to increased liver-related mortality and morbidity. The Fast™ Score is a combination of three components: physical biomarkers liver stiffness by VCTE™ and CAP™ estimating fibrosis and steatosis from an examination with FibroScan®, plus AST, a readily available blood marker of inflammation.

3/ FibroMeter VCTE™ is a diagnostic tool comprising both biochemical markers and transient elastography (TE) originally developed for the diagnosis of fibrosis in patients with chronic viral hepatitis. Preliminary findings indicate that FibroMeter VCTE is superior to both NAFLD fibrosis score (NFSA) and transient elastography (TE) for the diagnosis of severe fibrosis in patients with NAFLD.


Important Conference

The AASLD conference allowed us to showcase FibroScan® as a valuable innovation that can improve care and reduce costs for managing chronic liver conditions. The expanding body of data supports FibroScan® as an early assessment and monitoring tool that can mitigate the risk that patients will develop more serious conditions like fibrosis, cirrhosis and liver cancer.

chevron AASLD Wrap Up; Key Lessons in NAFLD NASH Diagnostic Strategies